Home/Filings/4/0001193125-25-308354
4//SEC Filing

TABUTEAU HERRIOT 4

Accession 0001193125-25-308354

CIK 0001579428other

Filed

Dec 3, 7:00 PM ET

Accepted

Dec 4, 7:39 PM ET

Size

20.1 KB

Accession

0001193125-25-308354

Insider Transaction Report

Form 4
Period: 2025-12-02
TABUTEAU HERRIOT
DirectorChief Executive Officer10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-02$8.02/sh+49,252$395,00156,481 total
  • Sale

    Common Stock

    2025-12-02$144.59/sh49,252$7,121,3477,229 total
  • Exercise/Conversion

    Common Stock

    2025-12-03$8.02/sh+20,163$161,70727,392 total
  • Sale

    Common Stock

    2025-12-03$146.94/sh20,163$2,962,7517,229 total
  • Exercise/Conversion

    Common Stock

    2025-12-04$8.02/sh+10,558$84,67517,787 total
  • Sale

    Common Stock

    2025-12-04$148.18/sh10,558$1,564,4847,229 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-0249,252202,545 total
    Exercise: $144.59From: 2017-05-27Exp: 2026-05-27Common Stock (49,252 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-0320,163182,382 total
    Exercise: $146.94From: 2017-05-27Exp: 2026-05-27Common Stock (20,163 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-0410,558171,824 total
    Exercise: $148.18From: 2017-05-27Exp: 2026-05-27Common Stock (10,558 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    7,344,500
Footnotes (7)
  • [F1]Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
  • [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
  • [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
  • [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $141.79 and $149.23.
  • [F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $142.66 and $148.39.
  • [F6]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $146.77 and $149.41.
  • [F7]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

Documents

1 file

Issuer

Axsome Therapeutics, Inc.

CIK 0001579428

Entity typeother

Related Parties

1
  • filerCIK 0001219927

Filing Metadata

Form type
4
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 7:39 PM ET
Size
20.1 KB